Shares of Vical Incorporated (NASDAQ:VICL) have earned a consensus broker rating score of 1.50 (Buy) from the two analysts that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company.
Analysts have set a twelve-month consensus target price of $4.20 for the company and are predicting that the company will post ($0.17) EPS for the current quarter, according to Zacks. Zacks has also given Vical an industry rank of 51 out of 256 based on the ratings given to related companies.
VICL has been the subject of several research analyst reports. Zacks Investment Research downgraded shares of Vical from a “buy” rating to a “hold” rating in a research report on Saturday, January 5th. HC Wainwright set a $4.00 price target on shares of Vical and gave the company a “buy” rating in a research report on Tuesday, October 30th.
VICL stock traded down $0.01 on Friday, hitting $1.00. 16,157 shares of the company’s stock traded hands, compared to its average volume of 72,088. Vical has a 1-year low of $0.90 and a 1-year high of $1.92. The firm has a market cap of $24.33 million, a PE ratio of -0.99 and a beta of 0.65.
Vical (NASDAQ:VICL) last issued its quarterly earnings results on Monday, October 29th. The biotechnology company reported ($0.14) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.08. The business had revenue of $0.05 million during the quarter, compared to the consensus estimate of $0.18 million. Vical had a negative net margin of 300.44% and a negative return on equity of 31.61%. Equities analysts forecast that Vical will post -0.85 earnings per share for the current year.
Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company is developing VCL-HB01, an HSV-2 therapeutic vaccine that is in Phase II clinical trial to prevent and protect against lesion recurrence, as well as for the treatment of patients with symptomatic genital herpes infection; VL-2397 antifungal program, which is in Phase II clinical trial for the treatment of invasive fungal infections; and chronic hepatitis B that is in preclinical stage for the eradication of persistent HBV infection.
Read More: Derivative
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical and related companies with MarketBeat.com's FREE daily email newsletter.